Reports Q2 revenue $11.3B, consensus $9.92B. “Mounjaro, Zepbound and Verzenio led our strong financial performance in the second quarter as we advanced our manufacturing expansion agenda, and it is equally exciting to see the growth around the world of our medicines for cancer, neurological disorders and autoimmune diseases,” said David A. Ricks, Lilly’s chair and CEO. “We also recently received approval of Kisunla to help people with Alzheimer’s disease, a moment that was decades in the making. Lilly’s performance and progress in Alzheimer’s, metabolic disorders and many other serious diseases highlight the tenacity, focus and capability of our scientists, clinicians, engineers, customer teams and collaborators.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- European Stocks: Novo Nordisk Lowers Profit Outlook on Subdued Wegovy Sales
- Eli Lilly (NYSE:LLY) Branches Out into Nuclear Isotopes, Shares Melt Down
- European Stocks: Novo Nordisk Bets Big to Lead the Weight-Loss Market
- LLY Earnings this Week: How Will it Perform?
- Options Volatility and Implied Earnings Moves This Week, August 05 – August 09, 2024